ReviewBiomimetics (Basel, Switzerland)2026
Collagen Type I as a Biological Barrier Interface in Biomimetic Microfluidic Devices: Properties, Applications, and Challenges.
Review in Biomimetics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Osteoimmunology-Driven Design of Dental Implant Materials: From Immune Response to Osseointegration.Materials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collagen type I has become a practical cornerstone for constructing biologically meaningful barrier interfaces in microfluidic systems. Its fibrillar architecture, native ligand display, and susceptibility to cell-mediated remodeling support epithelial and endothelial polarization, tight junctions, and transport behaviors that are difficult to achieve with purely synthetic barrier interfaces. Recent advances pair these biological strengths with tighter engineering control. For example, ultrathin collagen barriers (tens of micrometers or less) enable faster molecular exchange and short-range signaling; gentle crosslinking and composite designs limit gel compaction and delamination under flow; and patterning/bioprinting introduce alignment, graded porosity, and robust integration into device geometries. Applications now span intestine, vasculature, skin, airway, kidney, and tumor-stroma interfaces, with readouts including transepithelial/transendothelial electrical resistance (TEER), tracer permeability, and image-based quality control of fiber architecture. Persistent constraints include batch variability, long-term mechanical drift, limited standardization of fibrillogenesis conditions, and difficulties scaling fabrication without loss of bioactivity. Priorities include reporting standards for microstructure and residual crosslinker, chips for continuous monitoring, immune-competent co-cultures, and closer collaboration across materials science, microfabrication, computational modelling, and clinical pharmacology. Thus, this review synthesizes the state-of-the-art and offers practical guidance on technological readiness and future directions for using collagen type I as a biological barrier interface in biomimetic microfluidic systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.